Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients-Reference-Cited by-同舟云学术

Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients

Published:2023-08-14 Issue:8 Volume:15 Page:1738
ISSN:1999-4915
Container-title:Viruses
language:en
Short-container-title:Viruses

Author:

Colapietro Francesca¹²^ORCID,Angelotti Giovanni¹³,Masetti Chiara²,Shiffer Dana¹⁴,Pugliese Nicola¹²^ORCID,De Nicola Stella²,Carella Francesco¹,Desai Antonio¹⁴^ORCID,Ormas Monica²,Calatroni Marta¹⁵^ORCID,Omodei Paolo⁶,Ciccarelli Michele⁷,Aliberti Stefano¹⁷,Reggiani Francesco¹⁵,Bartoletti Michele¹⁸,Cecconi Maurizio¹⁹,Lleo Ana¹²^ORCID,Aghemo Alessio¹²,Voza Antonio¹⁴^ORCID

Affiliation:

1. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy

2. Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Research Hospital IRCCS, 20089 Milan, Italy

3. Humanitas Artificial Intelligence Center, Humanitas Research Hospital IRCCS, 20089 Milan, Italy

4. Emergency Department, Humanitas Research Hospital IRCCS, 20089 Milan, Italy

5. Nephrology and Dialysis Unit, Humanitas Research Hospital IRCCS, 20089 Milan, Italy

6. Department of Gastroenterology, Division of Gastroenterology and Digestive Endoscopy, Humanitas Research Hospital IRCCS, 20089 Milan, Italy

7. Division of Respiratory Medicine, Humanitas Research Hospital IRCCS, 20089 Milan, Italy

8. Infectious Disease Unit, Humanitas Research Hospital IRCSS, 20089 Milan, Italy

9. Department of Anaesthesia and Intensive Care, Humanitas University IRCCS, 20090 Milan, Italy

Abstract

Ursodeoxycholic acid (UDCA) was demonstrated to reduce susceptibility to SARS-CoV-2 infection in vitro and improve infection course in chronic liver diseases. However, real-life evidence is lacking. We analyzed the impact of UDCA on COVID-19 outcomes in patients hospitalized in a tertiary center. Between January 2020 and January 2023, among 3847 patients consecutively hospitalized for COVID19, 57 (=UDCA group) were taking UDCA. The UDCA and the control groups (n = 3790) did not differ concerning comorbidities including diabetes mellitus type 2 (15.8% vs. 12.8%) and neoplasia (12.3% vs. 9.4%). Liver diseases and vaccination rate were more common in the UDCA group (14.0% vs. 2.5% and 54.4% vs. 30.2%, respectively). Overall mortality and CPAP treatment were 22.8 % and 15.7% in the UDCA, and 21.3% and 25.9% in the control group. Mortality was similar (p = 0.243), whereas UDCA was associated with a lower rate of CPAP treatment (OR = 0.76, p < 0.05). Treatment with UDCA was not an independent predictor of survival in patients hospitalized for COVID-19.

Publisher

MDPI AG

Subject

Virology,Infectious Diseases

Link

https://www.mdpi.com/1999-4915/15/8/1738/pdf

Reference26 articles.

1. (2023, February 16). Therapeutics and COVID-19. Available online: https://www.who.int/teams/health-care-readiness/COVID-19/therapeutics.

2. Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China;Yang;Eur. J. Med. Chem.,2023

3. Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses;Tomalka;Nat. Immunol.,2022

4. Remdesivir for the Treatment of COVID-19—Final Report;Beigel;N. Engl. J. Med.,2020

5. Remdesivir for 5 or 10 Days in Patients with Severe COVID-19;Goldman;N. Engl. J. Med.,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the impact of ursodeoxycholic acid therapy on COVID‐19 in a real‐word setting;Journal of Medical Virology;2024-01

2. Ursodeoxycholic acid and severe COVID-19 outcomes in people with liver disease: a cohort study using the OpenSAFELY platform;2023-12-13

3. Bile acids and bile acid activated receptors in the treatment of Covid-19;Biochemical Pharmacology;2023-12

4. Ursodeoxycholic acid does not affect the clinical outcome of SARS‐CoV‐2 infection: A retrospective study of propensity score‐matched cohorts;Liver International;2023-09-21